Novo’s Big 2030 Pitch Gets a Small Reception

Novo's Big 2030 Pitch Gets a Small Reception - Moby THE GIST Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Novo laid out an ambitious pipeline, more patients and billions in future drug sales, but investors wanted a clearer answer to the question hanging over the company: what replaces semaglutide when competition and patents catch up? The shares tumbled as management's long-term growth targets proved too broad to reassure a market already worried about Eli Lilly, pricing pressure and recent clinical setbacks.